JP2024508764A5 - - Google Patents

Info

Publication number
JP2024508764A5
JP2024508764A5 JP2023549992A JP2023549992A JP2024508764A5 JP 2024508764 A5 JP2024508764 A5 JP 2024508764A5 JP 2023549992 A JP2023549992 A JP 2023549992A JP 2023549992 A JP2023549992 A JP 2023549992A JP 2024508764 A5 JP2024508764 A5 JP 2024508764A5
Authority
JP
Japan
Prior art keywords
sequence number
antigen
antibody
binding fragment
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023549992A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024508764A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/016912 external-priority patent/WO2022178203A1/en
Publication of JP2024508764A publication Critical patent/JP2024508764A/ja
Publication of JP2024508764A5 publication Critical patent/JP2024508764A5/ja
Pending legal-status Critical Current

Links

JP2023549992A 2021-02-18 2022-02-18 抗ｖｉｓｔａ抗体及びその使用 Pending JP2024508764A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163150995P 2021-02-18 2021-02-18
US63/150,995 2021-02-18
PCT/US2022/016912 WO2022178203A1 (en) 2021-02-18 2022-02-18 Anti-vista antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2024508764A JP2024508764A (ja) 2024-02-28
JP2024508764A5 true JP2024508764A5 (enExample) 2025-02-26

Family

ID=82931719

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023549992A Pending JP2024508764A (ja) 2021-02-18 2022-02-18 抗ｖｉｓｔａ抗体及びその使用

Country Status (11)

Country Link
US (1) US20240132593A1 (enExample)
EP (1) EP4294530A4 (enExample)
JP (1) JP2024508764A (enExample)
KR (1) KR20230157970A (enExample)
CN (1) CN117177995A (enExample)
AU (1) AU2022223973A1 (enExample)
BR (1) BR112023016533A2 (enExample)
CA (1) CA3208872A1 (enExample)
IL (1) IL305310A (enExample)
MX (1) MX2023009623A (enExample)
WO (1) WO2022178203A1 (enExample)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3356415B1 (en) * 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
PE20250933A1 (es) * 2017-03-14 2025-04-02 Five Prime Therapeutics Inc Anticuerpos de union a vista a ph acido
PE20210687A1 (es) * 2018-07-11 2021-04-08 Bristol Myers Squibb Co Anticuerpos de union a vista a ph acido
WO2020140094A1 (en) * 2018-12-27 2020-07-02 Gigagen, Inc. Anti-b7-h3 binding proteins and methods of use thereof

Similar Documents

Publication Publication Date Title
JP7557567B2 (ja) Ｐｄ‐１結合分子及びその使用方法
JP7550591B2 (ja) 多重特異的ＮＫｐ４６結合タンパク質
US11202828B2 (en) Therapeutic SIRP-α antibodies
Godar et al. Therapeutic bispecific antibody formats: a patent applications review (1994-2017)
US20220098307A1 (en) Modified fc fragment, antibody comprising same, and application thereof
WO2015063187A1 (en) Multivalent antigen-binding proteins
JP2020500540A5 (enExample)
TW202208429A (zh) 用於治療多發性骨髓瘤之方法
KR20180021786A (ko) Lag-3-결합 분자 및 그 사용 방법
JP2023511482A (ja) Ｃｄ２７６抗原の抗体ターゲティング、および他のモジュレーター、ならびにその使用
CA2903056A1 (en) Tetravalent bispecific antibodies
US20230279108A1 (en) Therapeutic sirp-alpha antibodies
JP2023522730A5 (enExample)
JP2024508764A5 (enExample)
TW202525853A (zh) 抗ｃｄ２０ｘ抗ｃｄ２８組合療法
RU2023123926A (ru) Антитела к vista и их применение
JP7378567B2 (ja) Ｌａｇ‐３結合分子及びその使用方法
KR20240052030A (ko) 높은 열 안정성 및 감쇠된 효과기 기능을 갖는 fc 변이체
KR20260020402A (ko) 다발성 골수종의 치료 방법
Kiprijanov Bispecific antibodies and immune therapy targeting